EuroAPI EuroAPI

X
[{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Targovax Grants IOVaxis 3 Months Extension to the Exclusive License Option for TG Mutant RAS Vaccines in Greater China and Singapore","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Targovax"},{"orgOrder":0,"company":"ARTBIO","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"NORWAY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"ARTBIO"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The financing enables ARTBIO's ongoing clinical development of its lead program AB001 (212Pb-NG001) for the treatment of prostate cancer and will advance its AlphaDirect™ Pb212 isolation technology.

            Lead Product(s): 212Pb-NG001

            Therapeutic Area: Oncology Product Name: AB001

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: F-Prime Capital

            Deal Size: $23.0 million Upfront Cash: Undisclosed

            Deal Type: Financing June 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore.

            Lead Product(s): Apricoxib

            Therapeutic Area: Oncology Product Name: TG01

            Highest Development Status: IND Enabling Product Type: Vaccine

            Partner/Sponsor/Collaborator: IOVaxis Therapeutics

            Deal Size: $3.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 06, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY